Generate Biomedicines, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael T. Nally
- Full Time Employees
- 312
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 101 South Street Somerville MA United States of America 02143
- IPO Date
- Feb 27, 2026
- CIK
- 0002100782
- Website
- generatebiomedicines.com
- Similar Companies
- Business
- Generate:Biomedicines, Inc. conducts therapeutics design and development using computational, AI-driven biology to generate protein therapeutics across multiple disease areas. Core activities center on generative biology to identify, design, validate, and advance protein-based drug candidates from discovery through early clinical evaluation; it licenses AI-assisted platform capabilities, collaborates with pharmaceutical partners, and advances its own proprietary programs into clinical testing. Primary offerings include Generative Biology platform services; discovery and optimization of de novo protein therapeutics; target identification and validation; protein engineering and design for enhanced efficacy, safety, and manufacturability; in vitro and in vivo preclinical assessment; translational and early-phase clinical development support; strategic collaborations and licensing of its AI-driven platform and pipeline assets. The company focuses on immunology, infectious disease, and oncology pipelines, with a portfolio that includes computationally engineered monoclonal antibodies and other protein modalities. Geographic operations are centered in the United States, with headquarters in Somerville, Massachusetts, and facilities in Boynton Yards and Andover; it also engages with global partners for development, manufacturing, and clinical execution. Founded in 2018, Generate:Biomedicines operates as a biotechnology company leveraging its proprietary platform to generate and optimize novel protein therapeutics, pursuing partnerships and licensing as a route to product development and commercialization. Subsidiaries or affiliate arrangements are employed to support collaboration, development, and scale-up activities in conjunction with major pharma collaborators. The latest major changes include high-profile collaborations with global pharmaceutical companies to discover and develop protein therapeutics using the Generate Platform, advancement of multiple pipeline programs into clinical testing, and the ongoing expansion of its protein design and validation infrastructure in response to strategic partnerships and funding rounds.
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines Inc’s Quiet Period To End on April 8th (NASDAQ:GENB)
Market Today: Wall St. Rebounds; NVDA, AMZN, TGT in Focus
First Look: Target (TGT), Paramount (PSKY) and Gold in Focus
Market Today: Stocks Slide, Oil Majors Rally, Big Deals and FDA Setbacks
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
First Look: Iran Shock Roils Markets; Target Beats, Amazon Buys
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
Drug developer Generate Biomedicines raises $400 million in US IPO
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines aims to raise $425 million in US IPO
U.S. IPO Weekly Recap: IPO Market Stays Fairly Quiet During The Short Holiday Week
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Generate Biomedicines Begins IPO Push With Major Collaboration Deals